Literature DB >> 3522088

In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

P C Fuchs, R N Jones, A L Barry, C Thornsberry, L W Ayers, T L Gavan, E H Gerlach.   

Abstract

Cefixime, a new orally absorbed cephalosporin, was compared by in vitro testing with other oral beta-lactams, including cephalexin, cefaclor, cefuroxime, amoxicillin, and amoxicillin + clavulanate. Enterobacteriaceae were inhibited by lower concentrations of cefixime than any of the reference drugs; 90% and 95% were inhibited by less than or equal to 1.0 and less than or equal to 8.0 micrograms/ml, respectively. Cefixime was the least active among these drugs against staphylococci, with only 31% of 1106 strains inhibited by less than or equal to 8.0 micrograms/ml and less than 1% by less than or equal to 1.0 microgram/ml. Enterococci and pseudomonads were not susceptible to any of the drugs tested. Penicillin-resistant pneumococci were relatively resistant to cefixime, but penicillin-susceptible pneumococci were very susceptible to cefixime. Other streptococci were generally susceptible to all compounds tested, with relative activities of amoxicillin greater than cefaclor and cefuroxime greater than cefixime greater than cephalexin. Cefixime was inactive against Bacteroides species. A slight inoculum effect occurred with cefixime with inocolum concentrations varying from 10(5) to 10(6) colony forming units per milliliter, but this was more marked at 10(7) colony forming units per milliliter. Cefixime was resistant to hydrolysis by seven common beta-lactamases. It inhibited the hydrolysis of nitrocefin only by type 1 cephalosporinases. The disk diffusion zone diameter breakpoints for the 30-micrograms cefixime disk were determined by regression analysis to be greater than or equal to 27 mm (susceptible) and less than or equal to 23 mm (resistant), respectively corresponding to minimal inhibitory concentration breakpoints of less than or equal to 1.0 and greater than or equal to 4.0 micrograms/ml. Because of the high interpretive error rate (13.8%) and the occurrence of these breakpoints on the parabolic portion of the regression curve, we recommend further evaluation of cefixime disks with lower potencies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522088     DOI: 10.1016/0732-8893(86)90117-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

1.  Comparative in vitro activities of amoxicillin-clavulanic acid, cefuroxime, cephalexin, and cephalothin against trimethoprim-resistant Escherichia coli isolated from stools of children attending day-care centers.

Authors:  K V Singh; R R Reves; L K Pickering; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.

Authors:  A Kuhlwein; B A Nies
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

4.  Methods for predicting susceptibility of Streptococcus pneumoniae to cefixime.

Authors:  A L Barry; P C Fuchs
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

5.  Comparative in vitro activity of cefixime against Haemophilus influenzae isolates, including ampicillin-resistant, non-beta-lactamase-producing isolates, from pediatric patients.

Authors:  J E Mortensen; S L Himes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.

Authors:  D R Nash; C Flanagan; L C Steele; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

7.  Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

8.  Cefixime disk susceptibility test criteria.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

Review 9.  Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.

Authors:  R N Brogden; D M Campoli-Richards
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.